Holen Sie sich die Stockscreener-App
10.45
0.85%
-0.09
Schlusskurs vom Vortag:
$10.54
Offen:
$10.6
24-Stunden-Volumen:
437.78K
Relative Volume:
0.56
Marktkapitalisierung:
$719.08M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-5.7418
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+6.20%
1M Leistung:
+24.11%
6M Leistung:
+19.84%
1J Leistung:
+17.02%
1-Tages-Spanne:
$10.26
$10.77
1-Wochen-Bereich:
$9.79
$11.08
52-Wochen-Spanne:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
10.45 | 677.11M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
Is EyePoint Pharmaceuticals Inc. a good long term investmentSkyrocketing investment returns - jammulinksnews.com
What drives EyePoint Pharmaceuticals Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
What analysts say about EyePoint Pharmaceuticals Inc. stockTremendous return on equity - jammulinksnews.com
EyePoint Pharmaceuticals Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards 63,900 Shares in Employee Stock Options Under NASDAQ Rule - Stock Titan
EyePoint Pharmaceuticals Acquisition by Federated Hermes Highlights Interest in Healthcare Sector - AInvest
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyFree Insider Trading Tips - beatles.ru
Pleasing Signs As A Number Of Insiders Buy EyePoint Pharmaceuticals Stock - simplywall.st
EyePoint Pharmaceuticals (EYPT) Soars 10.15% on Clinical Trial Progress - AInvest
Trend Tracker for (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) dropped from Russell 3000E Growth Index - MarketScreener
EyePoint Pharmaceuticals Approves Share Increase at Annual Meeting - TipRanks
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga
RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus
EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus
EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan
(EYPT) Trading Report - news.stocktradersdaily.com
EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha
Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada
Breakout Momentum Plays You May Not Know About - Investing.com
Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Cookies Notice - EyePoint Pharmaceuticals
ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com Nigeria
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):